You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Johnson and Johnson
Baxter
Dow
McKesson

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

Claims for Patent: RE43316

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: RE43316
Title:Diabetes management system and method for controlling blood glucose
Abstract: A diabetes management system for predicting a future blood glucose value of a patient and for recommending a corrective action to the patient when the future blood glucose value lies outside of a target range. The system includes a patient-operated apparatus for measuring blood glucose values and for storing data relating to insulin doses administered to the patient. The apparatus predicts the patient\'s future blood glucose value based upon the patient\'s current blood glucose value, the fraction of insulin action remaining from the insulin doses, and the patient\'s insulin sensitivity. The apparatus also determines the corrective action for the patient when the predicted blood glucose value lies outside of a target range. The system also includes a physician computer in communication with the apparatus for receiving the blood glucose values and insulin dose data and for calculating an adjusted insulin sensitivity for use in subsequent predictions.
Inventor(s): Brown; Stephen J. (Woodside, CA), Worthington; David L. (La Honda, CA)
Assignee: Health Hero Network, Inc. (Palo Alto, CA)
Application Number:10/950,226
Patent Claims:1. An apparatus for assisting a patient having diabetes mellitus in controlling blood glucose, said apparatus comprising: a) an input means for entering a blood glucose value G(t.sub.d) representative of a blood glucose concentration of the patient at time t.sub.d and for entering an insulin dose value I.sub.k representative of an insulin dose administered to the patient prior to time t.sub.d; b) a memory means for storing an insulin sensitivity value representative of an insulin sensitivity of the patient and for storing information for determining an insulin action value F.sub.k(2.sup.d) representative of a fraction of insulin action remaining at time t.sub.d from said insulin dose; c) a processor connected to said input means and said memory means for determining said insulin action value F.sub.k(t.sub.d) and for determining a future blood glucose value G(t.sub.j) representative of an expected blood glucose concentration of the patient at time t.sub.j, wherein said processor determines said future blood glucose value G(t.sub.j) in dependence upon said blood glucose value G(t.sub.d), said insulin dose value I.sub.k, said insulin sensitivity value, and said insulin action value F.sub.k(t.sub.d); d) an interpolation formula to calculate the insulin action value F.sub.k(t.sub.d) programmed into the processor, the formula to calculate the insulin action value comprising F.sub.k(t.sub.d)=Y.sub.0+((Z.sub.k-X.sub.0)(Y.sub.1-Y.sub.0)/(X.sub.1-X.s- ub.0)) wherein X.sub.0 represents an initial insulin dose, Y.sub.0 represents an insulin action value at initial dose X.sub.0, X.sub.1 represents a following insulin dose, Y.sub.1 represents an insulin action value at following insulin dose X.sub.1, and Z.sub.k represents time after injection of insulin dose I.sub.k at time t.sub.d; e) a formula to calculate the future blood glucose value G(t.sub.j) programmed into the processor, the formula to calculate the food glucose value comprising: .function..function..function..times..times..function..function. ##EQU00008## wherein S represents insulin sensitivity values, I.sub.k represents insulin dose values administered prior to time t.sub.d, and F.sub.k(t.sub.j) represents insulin action values at time (t.sub.j), k=1 represents a single insulin bolus dose and a supplemental insulin bolus dose, and N represents the total number of insulin bolus doses and supplemental insulin bolus doses; and f) a display means connected to said processor for displaying said future blood glucose value G(t.sub.j), thereby enabling the patient to take timely corrective action to prevent hypoglycemia or hyperglycemia.

2. The apparatus of claim 1, wherein said memory means includes means for storing maximum and minimum values defining a target blood glucose range of the patient, said processor includes means for determining if said future blood glucose value G(t.sub.j) lies outside of said target range and means for determining said corrective action for the patient when said future blood glucose value G(t.sub.j) lies outside of said target range, and said display means includes means for recommending said corrective action to the patient.

3. The apparatus of claim 2, wherein said memory means further includes means for storing a target blood glucose value of the patient, said corrective action comprises an administration of a supplemental insulin dose, and said processor further comprises means for determining said supplemental insulin dose in dependence upon said insulin sensitivity value and a difference between said future blood glucose value G(t.sub.j) and said target blood glucose value.

4. The apparatus of claim 2, wherein said memory means further includes means for storing a target blood glucose value of the patient, said corrective action comprises a consumption of a number of grams of carbohydrates, and said processor further comprises means for determining said number of grams in dependence upon a difference between said future blood glucose value G(t.sub.j) and said target blood glucose value.

5. The apparatus of claim 1, wherein said memory means further includes means for storing a hypoglycemic value indicative of a hypoglycemic threshold of the patient, said processor includes means for determining if said future blood glucose value G(t.sub.j) lies below said hypoglycemic value, and said apparatus further comprises audio means connected to aid processor for audibly alerting the patient when said future blood glucose value G(t.sub.j) lies below said hypoglycemic value.

6. The apparatus of claim 1, wherein said input means comprises a blood glucose measuring means for measuring a blood sample of the patient and for producing said blood glucose value G(t.sub.d) from a measurement of said blood sample.

7. The apparatus of claim 1, wherein said insulin dose has an insulin type, said input means includes means for entering said insulin type, and said processor includes means for determining said insulin action value F.sub.k(t.sub.d) in dependence upon said insulin type.

8. The apparatus of claim 7, wherein said insulin type is selected from the group consisting of regular insulin and lispro insulin.

9. The apparatus of claim 1, wherein said processor includes means for determining an insulin action value F.sub.k(t.sub.j) representative of a fraction of insulin action remaining at time t.sub.j from said insulin dose and means for determining said future blood glucose G(t.sub.j) in further dependence upon said insulin action value F.sub.k(t.sub.j).

10. The apparatus of claim 1, wherein said processor includes means for determining an ultimate time point at which said insulin dose will have no insulin action remaining and means for setting time t.sub.j equal to said ultimate time point.

11. The apparatus of claim 1, wherein said processor includes means for determining a plurality of future blood glucose values representative of a corresponding plurality of expected blood glucose concentrations of the patient, and wherein said display means includes means for displaying said future blood glucose values in graphical form.

12. The apparatus of claim 1, further comprising a communication means connected to said processor for establishing a communication link between said apparatus and a healthcare provider computer and for transmitting and receiving data therebetween.

13. The apparatus of claim 12, wherein said communication means comprises a modem means for establishing said communication link through a communication network.

14. The apparatus of claim 12, wherein said communication means comprises an input/output port for establishing said communication link through a connection cord.

15. A system for assisting a patient having diabetes mellitus in controlling blood glucose, said system comprising: a) an input means for entering a blood glucose value G(t.sub.d) representative of a blood glucose concentration of the patient at time t.sub.d and for entering an insulin dose value I.sub.k representative of an insulin dose administered to the patient prior to time t.sub.d; b) a memory means for storing maximum and minimum values defining a target blood glucose range of the patient, an insulin sensitivity value representative of an insulin sensitivity of the patient, and information for determining an insulin action value F.sub.k(t.sub.d) representative of a fraction of insulin action remaining at time t.sub.d from said insulin dose; c) a processor connected to said input means and said memory means for determining said insulin action value F.sub.k(t.sub.d), for determining a future blood glucose value G(t.sub.j) representative of an expected blood glucose concentration of the patient at time t.sub.j, and for determining a corrective action for the patient when said future blood glucose value G(t.sub.j) lies outside of said target range, wherein said processor determines said future blood glucose value G(t.sub.j) in dependence upon said blood glucose value G(t.sub.d), said insulin dose value, said insulin sensitivity value, and said insulin action value F.sub.k(t.sub.d); and d) an interpolation formula to calculate the insulin action value F.sub.k(t.sub.d) programmed into the processor, the formula to calculate the insulin action value comprising: F.sub.k(t.sub.d)=Y.sub.0+((Z.sub.k-X.sub.0)(Y.sub.1-Y.sub.0)/(X.sub.1-X.s- ub.0)) wherein X.sub.0 represents an initial insulin dose, Y.sub.0 represents an insulin action value at initial dose X.sub.0, X.sub.1 represents a following insulin dose, Y.sub.1, represents an insulin action value at following insulin dose X.sub.1, and Z.sub.k represents time after injection of insulin dose I.sub.k at time t.sub.d; e) a formula to calculate the future blood glucose value G(t.sub.j) programmed into the processor, the formula to calculate the food glucose value comprising. .function..function..function..times..times..function..function. ##EQU00009## wherein S represents insulin sensitivity values, I.sub.k represents insulin dose values administered prior to time t.sub.d, and F.sub.k(t.sub.j) represents insulin action values at time (t.sub.j), k=1 represents a single insulin bolus dose and a supplemental insulin bolus dose, and N represents the total number of insulin bolus doses and supplemental insulin bolus doses; and f) a display means connected to said processor for recommending said corrective action to the patient.

16. The system of claim 15, wherein said memory means further includes means for storing a target blood glucose value of the patient, said corrective action comprises an administration of a supplemental insulin dose, and said processor further comprises means for determining said supplemental insulin dose in dependence upon said insulin sensitivity value and a difference between said future blood glucose value G(t.sub.j) and said target blood glucose value.

17. The system of claim 15, wherein said memory means further includes means for storing a target blood glucose value of the patient, said corrective action comprises a consumption of a number of grams of carbohydrates, and said processor further comprises means for determining said number of grams in dependence upon a difference between said future blood glucose value G(t.sub.j) and said target blood glucose value.

18. The system of claim 15, wherein said memory means further includes means for storing a hypoglycemic value indicative of a hypoglycemic threshold of the patient, said processor includes means for determining if said future blood glucose G(t.sub.j) lies below said hypoglycemic value, and said system further comprises audio means connected to said processor for audibly alerting the patient when said future blood glucose value G(t.sub.j) lies below said hypoglycemic value.

19. The system of claim 15, wherein said input means comprises a blood glucose measuring means for measuring a blood sample of the patient and for producing said blood glucose value G(t.sub.d) from a measurement of said blood sample.

20. The system of claim 15, wherein said insulin dose has an insulin type, said input means includes means for entering said insulin type, and said processor includes means for determining said insulin action value F.sub.k(t.sub.d) in dependence upon said insulin type.

21. The system of claim 20, wherein said insulin type is selected from the group consisting of regular insulin and lispro insulin.

22. The system of claim 15, wherein said processor includes means for determining an insulin action value F.sub.k(t.sub.j) representative of a fraction of insulin action remaining at time t.sub.j from said insulin dose and means for determining said future blood glucose value G(t.sub.j) in further dependence upon said insulin action value F.sub.k(t.sub.j).

23. The system of claim 15, wherein said processor includes means for determining an ultimate time point at which said insulin dose will have no insulin action remaining and means for setting time t.sub.j equal to said ultimate time point.

24. The system of claim 15, wherein said processor includes means for determining a plurality of future blood glucose values representative of a corresponding plurality of expected blood glucose concentrations of the patient, and wherein said display means includes means for displaying said future blood glucose values in graphical form.

25. The system of claim 15, wherein said input means includes means for entering a plurality of blood glucose values and a plurality of insulin dose values, and said system further comprises a computing means in communication with said processor for receiving said blood glucose values and said insulin dose values and for calculating from said blood glucose values and said insulin dose values an adjusted insulin sensitivity value.

26. The system of claim 25, wherein said input means, said memory means, said processor, and said display means are included in a patient-operated apparatus, said computing means comprises a healthcare provider computer, and said apparatus includes a communication means connected to said processor for establishing a communication link between said apparatus and said healthcare provider computer.

27. The system of claim 26, wherein said communication means comprises a modem means for establishing said communication link through a communication network.

28. The system of claim 26, wherein said communication means comprises an input/output port for establishing said communication link through a connection cord.

29. A method for assisting a patient having diabetes mellitus in controlling blood glucose, said method comprising the following steps: a) providing the patient with an apparatus for determining a future blood glucose value G(t.sub.j) representative of an expected blood glucose concentration of the patient at time t.sub.j, wherein said apparatus comprises a memory, an input means for entering a blood glucose value G(t.sub.d) representative of a blood glucose concentration of the patient at time t.sub.d and for entering an insulin dose value representative of an insulin dose administered to the patient prior to time t.sub.d, a display, and a processor connected to said memory, said input means, and said display; b) storing in said memory an insulin sensitivity value representative of an insulin sensitivity of the patient; c) storing in said memory information for determining an insulin action value F.sub.k(t.sub.d) representative of a fraction of insulin action remaining at time t.sub.d from said insulin dose; d) entering in said processor said insulin dose value and said blood glucose value G(t.sub.d); e) determining in said processor said insulin action value F.sub.k(t.sub.d) by programming the processor to execute an interpolation formula to calculate the insulin action value F.sub.k(t.sub.d) programmed into the processor, the formula to calculate the insulin action value comprising: F.sub.k(t.sub.d)=Y.sub.0+((Z.sub.k-X.sub.0)(Y.sub.1-Y.sub.0)/(X.sub.1-X.s- ub.0)) wherein X.sub.0 represents an initial insulin dose, Y.sub.0 represents an insulin action value at initial dose X.sub.0, X.sub.1 represents a following insulin dose, Y.sub.1 represents an insulin action value at following insulin dose X.sub.1, and Z.sub.k represents time after injection of insulin dose I.sub.k at time t.sub.d; f) determining in said processor said future blood glucose value G(t.sub.j) in dependence upon said blood glucose value G(t.sub.d), said insulin dose value, said insulin sensitivity value, and said insulin action value F.sub.k(t.sub.d) by programming the processor to execute a formula to calculate the future blood glucose value G(t.sub.j) programmed into the processor, the formula to calculate the food glucose value comprising: .function..function..function..times..times..function..function. ##EQU00010## wherein S represents insulin sensitivity values, I.sub.k represents insulin dose values administered prior to time t.sub.d, and F.sub.k(t.sub.j) represents insulin action values at time (t.sub.j), k=1 represents a single insulin bolus dose and a supplemental insulin bolus dose, and N represents the total number of insulin bolus doses and supplemental insulin bolus doses; and g) displaying said future blood glucose value G(t.sub.j) on said display, thereby enabling the patient to take timely corrective action to prevent hypoglycemia or hyperglycemia.

30. The method of claim 29, further comprising the step of determining in said processor an insulin action value F.sub.k(t.sub.j) representative of a fraction of insulin action remaining at time t.sub.j, from said insulin dose, and wherein said future blood glucose value G(t.sub.j) is determined in further dependence upon said insulin action value F.sub.k(t.sub.j).

31. The method of claim 29, wherein the step of determining said future blood glucose value G(t.sub.j) is preceded by the steps of determining in said processor an ultimate time point at which said insulin dose will have no insulin action remaining and setting time t.sub.j equal to said ultimate time point.

32. The method of claim 29, further comprising the steps of determining in said processor a plurality of future blood glucose values representative of a corresponding plurality of expected blood glucose concentrations of the patient and displaying said future blood glucose values in graphical form on said display.

33. The method of claim 29, further comprising the steps of storing in said memory maximum and minimum values defining a target blood glucose range of the patient, determining in said processor if said future blood glucose value G(t.sub.j) lies outside of said target range, determining in said processor said corrective action for the patient when said future blood glucose value G(t.sub.j) lies outside of said target range, and recommending said corrective action on said display.

34. The method of claim 33, wherein said corrective action comprises an administration of a supplemental insulin dose, and said method further comprises the steps of storing in said memory a target blood glucose value of the patient and determining in said processor said supplemental insulin dose in dependence upon said insulin sensitivity value and a difference between said future blood glucose value G(t.sub.j) and said target blood glucose value.

35. The method of claim 33, wherein said corrective action comprises a consumption of a number of grams of carbohydrates, and said method further comprises the steps of storing in said memory a target blood glucose value of the patient and determining in said processor said number of grams in dependence upon a difference between said future blood glucose value G(t.sub.j).

36. The method of claim 29, further comprising the steps of storing in said memory a hypoglycemic value indicative of a hypoglycemic threshold of the patient, determining in said processor if said future blood glucose value G(t.sub.j) lies below said hypoglycemic value, and audibly alerting the patient when said future blood glucose value G(t.sub.j) lies below said hypoglycemic value.

37. The method of claim 29, wherein said input means comprises a blood glucose meter and the step of entering said blood glucose value G(t.sub.d) comprises the steps of measuring a blood sample of the patient with said glucose meter and producing said blood glucose value G(t.sub.d) from a measurement of said blood sample.

38. The method of claim 29, wherein said insulin dose has an insulin type, said method further comprises the step of entering said insulin type in said processor, and said insulin action value F.sub.k(t.sub.d) is determined in dependence upon said insulin type.

39. The method of claim 38, wherein said insulin type is selected from the group consisting of regular insulin and lispro insulin.

40. A method for assisting a patient having diabetes mellitus in controlling blood glucose, said method comprising the following steps: a) providing the patient with an apparatus for determining a future blood glucose value G(t.sub.j) representative of an expected blood glucose concentration of the patient at time t.sub.j, wherein said apparatus comprises a memory, an input means for entering a blood glucose value G(t.sub.d) representative of a blood glucose concentration of the patient at time t.sub.d and for entering an insulin dose value representative of an insulin dose administered to the patient prior to time t.sub.d, a display, an a processor connected to said memory, said input means, and said display; b) storing in said memory an insulin sensitivity value representative of an insulin sensitivity of the patient, information for determining an insulin action value F.sub.k(t.sub.d) representative of a fraction of insulin action remaining at time t.sub.d from said insulin dose, and maximum and minimum values defining a target blood glucose range of the patient; c) entering in said processor said insulin dose value and said blood glucose value G(t.sub.d); d) determining in said processor said insulin action value F.sub.k(t.sub.d) by programming the processor to execute an interpolation formula to calculate the insulin action value F.sub.k(t.sub.d) as stated in the formula to calculate the insulin action value comprising: F.sub.k(t.sub.d)=Y.sub.0+((Z.sub.k-X.sub.0)(Y.sub.1-Y.sub.0)/(X.sub.1-X.s- ub.0)) wherein X.sub.0 represents an initial insulin dose, Y.sub.0 represents an insulin action value at initial dose X.sub.0, X.sub.1 represents a following insulin dose, Y.sub.1 represents an insulin action value at following insulin dose X.sub.1, and Z.sub.k represents time after injection of insulin dose I.sub.k at time t.sub.d; e) determining in said processor said future blood glucose value G(t.sub.j) by programming the processor to execute a formula to calculate the future blood glucose value G(t.sub.j) using the formula to calculate the food glucose value comprising: .function..function..function..times..times..function..function. ##EQU00011## wherein S represents insulin sensitivity values, I.sub.k represents insulin dose values administered prior to time t.sub.d, and F.sub.k(t.sub.j) represents insulin action values at time (t.sub.j), k=1 represents a single insulin bolus dose and a supplemental insulin bolus dose, and N represents the total number of insulin bolus doses and supplemental insulin bolus doses, and in dependence upon said blood glucose value G(t.sub.d), said insulin dose value, said insulin sensitivity value, and said insulin action value F.sub.k(t.sub.d); f) determining in said processor if said future blood glucose value G(t.sub.j) lies outside of said target range; g) determining in said processor a corrective action for the patient when said future blood glucose value G(t.sub.j) lies outside of said target range; and h) recommending said corrective action to the patient on said display.

41. The method of claim 40, further comprising the step of determining in said processor an insulin action value F.sub.k(t.sub.j) representative of a fraction of insulin action remaining at time t.sub.j from said insulin dose, and wherein said future blood glucose value G(t.sub.j) is determined in further dependence upon said insulin action value F.sub.k (t.sub.j).

42. The method of claim 40, wherein the step of determining said future blood glucose value G(t.sub.j) is preceded by the steps of determining in said processor an ultimate time point at which said insulin dose will have no insulin action remaining and setting time t.sub.j equal to said ultimate time point.

43. The method of claim 40, further comprising the steps of determining in said processor a plurality of future blood glucose values representative of a corresponding plurality of expected blood glucose concentrations of the patient and displaying said future blood glucose values in graphical form on said display.

44. The method of claim 40, wherein said corrective action comprises an administration of a supplemental insulin dose, and said method further comprises the steps of storing in said memory a target blood glucose value of the patient and determining in said processor said supplemental insulin dose in dependence upon said insulin sensitivity value and a difference between said future blood glucose value G(t.sub.j) and said target blood glucose value.

45. The method of claim 40, wherein said corrective action comprises a consumption of a number of grams of carbohydrates, and said method further comprises the steps of storing in said memory a target blood glucose value of the patient and determining in said processor said number of grams in dependence upon a difference between said future blood glucose value G(t.sub.j) and said target blood glucose value.

46. The method of claim 40, further comprising the steps of storing in said memory, a hypoglycemic value indicative of a hypoglycemic threshold of the patient, determining in said processor if said future blood glucose value G(t.sub.j) lies below said hypoglycemic value, and audibly alerting the patient when said future blood glucose value G(t.sub.j) lies below said hypoglycemic value.

47. The method of claim 40, wherein said input means comprises a blood glucose meter and the step of entering said blood glucose value G(t.sub.d) comprises the steps of measuring a blood sample of the patient with said glucose meter and producing said blood glucose value G(t.sub.d) from a measurement of said blood sample.

48. The method of claim 40, wherein said insulin dose has an insulin type, said method further comprises the steps of entering said insulin type in said processor, and wherein said insulin action value F.sub.k(t.sub.d) is determined in dependence upon said insulin type.

49. The method of claim 48, wherein said insulin type is selected from the group consisting of regular insulin and lispro insulin.

50. The method of claim 40, further comprising the steps of entering in said processor a plurality of blood glucose values and a plurality of insulin dose values, determining from said glucose values and said insulin dose values an adjusted insulin dose values an adjusted insulin sensitivity value, and storing said adjusted insulin sensitivity value in said memory.

Details for Patent RE43316

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Sanofi-aventis Us ADMELOG insulin lispro SOLUTION;INTRAVENOUS, SUBCUTANEOUS 209196 001 2018-10-19   Start Trial Health Hero Network, Inc. (Palo Alto, CA) 2017-01-10 RX search
Sanofi-aventis Us ADMELOG SOLOSTAR insulin lispro SOLUTION;INTRAVENOUS, SUBCUTANEOUS 209196 002 2018-10-19   Start Trial Health Hero Network, Inc. (Palo Alto, CA) 2017-01-10 RX search
Sanofi-aventis Us ADMELOG insulin lispro SOLUTION;INTRAVENOUS, SUBCUTANEOUS 209196 003 2018-10-19   Start Trial Health Hero Network, Inc. (Palo Alto, CA) 2017-01-10 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
McKesson
Colorcon
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.